Paolo Senin

This inventor holds 11 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignees: Rotta Research Laboratorium, Rottapharm Spa, Rotta Research Laboratories S.p.a.. Active years: 1976-2017.

USPTO Granted Patents = 11 (Patent Applications = 2)

% Patents Active = 90.9

EPO Patents = 3

Average Co-Inventor Count = 3.3

ph-index = 5

Forward Citations = 74(Granted Patents)

Location History:

Monza (Milan), IT (1976 - 1977)
Monza, IT (1981 - 2017)

Company Filing History:

8 out of 33

Rotta Research Laboratorium

Rotta Research Laboratories S.p.a.

patents

Years Active: 1976-2017

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9623108 - Formulation for oral administration with beneficial effects on the cardiovascular system (2017-04-18),

2. 7824710 - Crystalline and stable form of andolast (2010-11-02),

3. 7025998 - Phytoestrogens and probiotic for women's health (2006-04-11),

4. 5976576 - Pharmaceutical composition for inhalation containing CR 2039 (Andolast) (1999-11-02),

5. 4791215 - Derivatives of glutamic acid and aspartic acid (1988-12-13),

6. 4642340 - Stable compounds of glucosamine sulphate (1987-02-10),

7. 4576951 - Proglumide, pharmaceutical preparations and compositions including it (1986-03-18),

8. 4288609 - Quaternary ammonium derivatives of adamantane with antimicrobic activity (1981-09-08),

9. 4272538 - 5-Nitro-imidazole with antiprotozoic activity (1981-06-09),

10. 4004008 - O-Tertiary amino-alkyl-N-benzoyl tyrosil amides (1977-01-18),

11. 3985878 - Anti-inflammatory and antirheumatic compounds and preparation (1976-10-12),

Title: Paolo Senin: Innovator in Cardiovascular Health

Introduction

Paolo Senin is a notable inventor based in Monza, Italy, recognized for his contributions to the field of cardiovascular health. With a total of 11 patents, Senin has made significant strides in developing formulations that promote heart health and overall well-being.

Latest Patents

Senin's latest patents include a formulation for oral administration that exerts beneficial effects on the cardiovascular system. This formulation, available in the form of tablets or powder for extemporaneous use, is designed to lower cholesterol and triglyceride levels while providing antioxidant activity and protective action on the vasal endothelium. It comprises berberine in combination with policosanol and/or red yeast, and preferably contains antioxidants such as astaxanthin and/or folic acid. Another significant patent is the crystalline and stable form of Andolast disodium salt, which displays remarkable stability under various humidity conditions. This new crystalline Form A of Andolast is not hygroscopic and allows for consistent and reproducible manufacturing processes.

Career Highlights

Throughout his career, Senin has worked with reputable companies such as Rotta Research Laboratorium and Rottapharm Spa. His work has focused on creating innovative solutions that address critical health issues, particularly in the cardiovascular domain.

Collaborations

Senin has collaborated with esteemed colleagues, including Francesco Makovec and Luigi A Rovati, contributing to the advancement of research and development in his field.

Conclusion

Paolo Senin's innovative work in cardiovascular health has led to the development of several impactful patents. His dedication to improving health outcomes through scientific research continues to inspire advancements in the medical field.